Printer Friendly

Frovatriptan works well for menstrual migraine.


LONDON--Frovatriptan may be the triptan of choice for the acute treatment of menstrual migraine attacks, according to reanalyses of data from double-blind, randomized crossover trials involving the drug.

Frovatriptan's lengthy half-life--the longest of all the triptans--and prolonged duration of clinical effect make it a particularly attractive option for the treatment of menstrual migraine attacks, which are typically longer in duration and more susceptible to relapse than migraine not related to menstruation, said Dr. Lidia Savi, a neurologist at the University of Turin (Italy).

At the congress, she presented a secondary analysis of data from a published, double-blind, randomized, multicenter crossover trial of frovatriptan (Frova) versus almotriptan (Axert) for the acute treatment of migraine (J. Headache Pain 2011;12:361-8).

Both men and women were included in the parent study.

The newer secondary analysis was restricted to the 67 participants with regular menstrual cycles.

In 155 menstrual migraine attacks treated in double-blind fashion, the two triptans displayed similar short-term efficacy, as reflected in pain relief and pain-free episodes 2 and 4 hours post treatment.

However, the recurrence rate within 48 hours after treatment was just 9% in frovatriptan-treated episodes, significantly less than the 24% rate for almotriptan (J. Headache Pain 2012;13: 401-6).

Dr. Gianni Allais presented a pooled analysis of Dr. Savi's study plus two other published Italian randomized, double-blind crossover clinical trials of frovatriptan versus rizatriptan (Maxalt) (J. Headache Pain 2011;12:609-15) and zolmitriptan (Zomig) (Neurol. Sci. 2011;32[suppl. 1]:S99-104). The pooled subgroup analysis covered the 187 women with at least one episode of menstrual migraine treated with frovatriptan and one episode treated with one of the other triptans.

Rates of being pain free and having pain relief 2 and 4 hours post treatment were similar across the board.

However, recurrence rates were significantly lower for frovatriptan-treated episodes than for those treated with any of the other agents.

At 24 hours of follow-up, the recurrence rate was 11% following frova-triptan versus 24% collectively for the comparator triptans. The 48-hour recurrence rate was 15% with frovatriptan, compared with 26% for the other triptans in this recently published pooled analysis (Neurol. Sci. 2012;33[suppl. 1]:S65-9), reported Dr. Allais of the women's headache center at the University of Turin.


Major Finding: The menstrual migraine recurrence rate 48 hours after treatment with frovatriptan was 15%, significantly less than the collective 26% rate after treatment with rizatriptan, zolmitriptan, or almotriptan.

Data Source: Data are from a post hoc pooled analysis of menstrually related migraine attacks in 187 women who participated in three double-blind, randomized, multicenter crossover trials of frovatriptan versus three other trip-tans for the acute treatment of migraine.

Disclosures: All three randomized trials as well the secondary analysis were funded by the Menarini Group, which markets frovatriptan in Italy. The presenters reported serving as consultants to the pharmaceutical company.
COPYRIGHT 2012 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CLINICAL ROUNDS
Author:Jancin, Bruce
Publication:OB GYN News
Date:Dec 1, 2012
Previous Article:Are hysterectomies really on the decline?
Next Article:Maryland moves ahead with insurance exchange: as an early adopter, the state offers a clue as to how health insurance exchanges may work.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters